日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Triple threat bismuth peptide imaging in cells

细胞内三重威胁铋肽成像

Voss, Saan; Kidman, Clinton J; Adair, Liam D; Nitschke, Samuel O; Patawanich, Pramsak; Koh, Terry; Baker, Ani T; Howard, Daryl L; New, Elizabeth J; Harris, Hugh H; Nitsche, Christoph

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Bimekizumab,一种可中和 IL-17A 和 IL-17F 的新型人源化 IgG1 抗体

Ralph Adams, Asher Maroof, Terry Baker, Alastair D G Lawson, Ruth Oliver, Ross Paveley, Steve Rapecki, Stevan Shaw, Pavan Vajjah, Shauna West, Meryn Griffiths

Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene

通过 CRISPR 介导的 SNCA 基因删除来设计抗突触核蛋白病的人类多巴胺能神经元

Yixi Chen, Karamjit Singh Dolt, Marco Kriek, Terry Baker, Patrick Downey, Nicola J Drummond, Maurice A Canham, Ammar Natalwala, Susan Rosser, Tilo Kunath

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

bimekizumab 在银屑病关节炎中对 IL-17A 和 IL-17F 的双重中和作用:临床前实验和随机安慰剂对照临床试验的证据表明 IL-17F 会导致人类慢性组织炎症

Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Alastair D G Lawson, Ash Maroof, Ruth Oliver, Serghei Popa, Foteini Strimenopoulou, Pavan Vajjah, Mark I L Watling, Nataliya Yeremenko, Pierre Miossec, Stevan Shaw

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau

表位决定治疗性抗 Tau 抗体在人类阿尔茨海默氏症 Tau 功能测定中的疗效

Jean-Philippe Courade, Rachel Angers, Georges Mairet-Coello, Nathalie Pacico, Kerry Tyson, Daniel Lightwood, Rebecca Munro, David McMillan, Robert Griffin, Terry Baker, Dale Starkie, Ruodan Nan, Marta Westwood, Marie-Laetitia Mushikiwabo, Sophie Jung, Geofrey Odede, Berni Sweeney, Andrew Popplewell,

Computational design of an epitope-specific Keap1 binding antibody using hotspot residues grafting and CDR loop swapping

使用热点残基移植和 CDR 环交换进行表位特异性 Keap1 结合抗体的计算设计

Xiaofeng Liu, Richard D Taylor, Laura Griffin, Shu-Fen Coker, Ralph Adams, Tom Ceska, Jiye Shi, Alastair D G Lawson, Terry Baker

Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life

通过生成人源化抗人血清白蛋白 Fv 结构域延长 fab 片段的半衰期:亲和力与血清半衰期相关性的研究

Ralph Adams, Laura Griffin, Joanne E Compson, Mark Jairaj, Terry Baker, Tom Ceska, Shauna West, Oliver Zaccheo, Emma Davé, Alastair Dg Lawson, David P Humphreys, Sam Heywood

Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

olokizumab 的发现和特性:一种靶向白细胞介素 6 并中和 gp130 信号的人源化抗体

Stevan Shaw, Tim Bourne, Chris Meier, Bruce Carrington, Rich Gelinas, Alistair Henry, Andrew Popplewell, Ralph Adams, Terry Baker, Steve Rapecki, Diane Marshall, Adrian Moore, Helen Neale, Alastair Lawson

Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention

白细胞介素-6 功能位点的保护及其对信号复合物组装和治疗干预进化的影响

Vaclav Veverka, Terry Baker, Nicholas T Redpath, Bruce Carrington, Frederick W Muskett, Richard J Taylor, Alastair D G Lawson, Alistair J Henry, Mark D Carr